Apidra initial u's approval 2004?

See the DrugPatentWatch profile for Apidra

What led to the approval of Apidra in 2004?

Apidra, also known as insulin glulisine, is a rapid-acting insulin analog used to control high blood sugar in people with diabetes. The insulin was approved by the FDA in 2004 for the treatment of diabetes [1].

How does Apidra compare to other rapid-acting insulins?

Apidra was the first rapid-acting insulin analog to be approved in the United States in 2004. It has a faster onset of action compared to human insulin, with a peak effect within 1 hour after administration. This property allows patients to have more flexibility in their meal planning and insulin dosing [2].

What are the potential benefits of Apidra?

Apidra has been shown to be effective in controlling blood sugar levels in patients with diabetes. Its rapid onset of action and short duration of action make it an ideal option for meal-time dosing [3].

When does Apidra's patent expire?

According to data available on DrugPatentWatch.com, the patent for Apidra will expire in 2017 [4]. After this date, other companies will be able to produce similar medications, which may increase competition and potentially lower prices.

References:

[1] FDA. (2004). Apidra (insulin glulisine) injection [package insert].

[2] Apidra Prescribing Information (Sanofi-Aventis).

[3] Apidra Clinical Trial Results (Sanofi-Aventis).

[4] DrugPatentWatch.com. Patent Expiration for Apidra (insulin glulisine)